The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Evidence of Benefit

Added text about a quadrivalent HPV vaccine that was evaluated in two multinational, double-blind, randomized controlled trials of 5,455 women aged 16 to 24 years and in 12,167 women aged 15 to 26 years (cited Garland et al. as reference 13 and FUTURE II Study Group as reference 14).

Added the Outcomes of the FUTURE I and FUTURE II HPV Vaccine Trials table.

Added text to state that no cases of invasive cervical cancer were identified during either trial.

Added text to state that as largely expected based upon their mechanism of action, L1/2 HPV vaccines do not appear to impact pre-existing infections (cited Hildesheim et al. as reference 15).

Added text to state that a meta-analysis of 25 epidemiologic studies including 16,563 women with cervical cancer and 33,542 women without, showed that the number of full-term pregnancies was associated with increased risk, regardless of age at first pregnancy (cited International Collaboration of Epidemiological Studies of Cervical Cancer as reference 20).

Back to Top

< Previous Section  |  Next Section >